BD and Opentrons Collaborate to Accelerate Single-Cell Multiomics Discoveries with Robotic Automation
BD (NYSE: BDX) and Opentrons announced a multi-year collaboration on Oct 8, 2025 to integrate Opentrons robotic liquid-handling into BD single-cell multiomics instruments.
The partnership intends to integrate the BD Rhapsody System with the Opentrons Flex platform, develop verified protocols, and build an automation-compatible module to automate next-generation sequencing library preparation and cell capture, enabling hands-free workflows and scaling to million-cell studies.
Early access opportunities will be available and both companies will present details at the ASHG Annual Meeting, Oct 14–18, 2025 (BD Booth 447; Opentrons Booth 635).
BD (NYSE: BDX) e Opentrons hanno annunciato una collaborazione pluriennale l'8 ottobre 2025 per integrare la gestione robotizzata dei liquidi di Opentrons negli strumenti BD single-cell multiomics.
La partnership intende integrare il sistema BD Rhapsody con la piattaforma Opentrons Flex, sviluppare protocolli verificati e costruire un modulo compatibile con l'automazione per automatizzare la preparazione delle librerie di sequencing di nuova generazione e la cattura delle cellule, consentendo flussi di lavoro hands-free e scalabilità a studi da milione di cellule.
Opportunità di accesso anticipato saranno disponibili e entrambe le aziende presenteranno dettagli al ASHG Annual Meeting, 14–18 ottobre 2025 (BD stand 447; Opentrons stand 635).
BD (NYSE: BDX) y Opentrons anunciaron una colaboración plurianual el 8 de octubre de 2025 para integrar el manejo robótico de líquidos de Opentrons en los instrumentos de BD multiómica de una sola célula.
La asociación tiene como objetivo integrar el sistema BD Rhapsody con la plataforma Opentrons Flex, desarrollar protocolos verificados y construir un módulo compatible con la automatización para automatizar la preparación de bibliotecas de secuenciación de próxima generación y la captura de células, habilitando flujos de trabajo sin intervención y escalando a estudios de millones de células.
Oportunidades de acceso anticipado estarán disponibles y ambas compañías presentarán detalles en la ASHG Annual Meeting, 14–18 de octubre de 2025 (BD Stand 447; Opentrons Stand 635).
BD (NYSE: BDX)와 Opentrons는 2025년 10월 8일에 Opentrons의 로봇 액체 취급 기술을 BD의 단일세포 다오믹스 기기에 통합하는 다년간의 협력을 발표했습니다.
파트너십의 목적은 BD Rhapsody 시스템을 Opentrons Flex 플랫폼과 통합하고, 검증된 프로토콜을 개발하며, 차세대 시퀀싱 라이브러리 준비 및 세포 포획을 자동화하는 자동화-호환 모듈을 구축하여 핸즈프리 워크플로를 가능하게 하고 백만 세포 연구로 확장하는 것입니다.
얼리 액세스 기회가 제공될 예정이며 두 회사는 ASHG Annual Meeting, 2025년 10월 14–18일에 자세한 내용을 발표할 예정입니다(BD 부스 447; Opentrons 부스 635).
BD (NYSE: BDX) et Opentrons ont annoncé le 8 octobre 2025 une collaboration pluriannuelle pour intégrer la manipulation robotisée de liquides d'Opentrons dans les instruments BD single-cell multiomics.
Le partenariat vise à intégrer le système BD Rhapsody avec la plateforme Opentrons Flex, développer des protocoles vérifiés et construire un module compatible avec l'automatisation pour automatiser la préparation des bibliothèques de séquençage de nouvelle génération et la capture cellulaire, permettant des flux de travail sans intervention et une mise à l'échelle pour des études d'un million de cellules.
Des opportunités d'accès anticipé seront disponibles et les deux entreprises présenteront les détails lors de l'ASHG Annual Meeting, du 14 au 18 octobre 2025 (Stand BD 447; Stand Opentrons 635).
BD (NYSE: BDX) und Opentrons kündigten am 8. Oktober 2025 eine mehrjährige Zusammenarbeit an, um die roboterbasierte Flüssigkeitshandhabung von Opentrons in BD Einzellzell-Multiomics-Instrumente zu integrieren.
Die Partnerschaft zielt darauf ab, das BD Rhapsody System mit der Opentrons Flex Plattform zu integrieren, verifizierte Protokolle zu entwickeln und ein automationskompatibles Modul zu bauen, um die Vorbereitung von Libraries für Next-Generation Sequencing und die Zellcapture zu automatisieren, freihändige Workflows zu ermöglichen und auf Studien mit Millionen von Zellen zu skalieren.
Early-Access-Möglichkeiten werden verfügbar sein und beide Unternehmen werden Details auf der ASHG Annual Meeting, 14.–18. Oktober 2025 vorstellen (BD Stand 447; Opentrons Stand 635).
BD (NYSE: BDX) وOpentrons أعلنتا في 8 أكتوبر 2025 عن تعاون يمتد لسنوات عديدة لدمج معالجة السوائل الروبوتية لـ Opentrons في أجهزة BD متعددة الخلايا أحادية الخلية.
يهدف الشراكة إلى دمج نظام BD Rhapsody مع منصة Opentrons Flex، وتطوير بروتوكولات مُوثقة وبناء وحدة متوافقة مع الأتمتة لأتمتة إعداد مكتبات التسلسل من الجيل التالي واحتجاز الخلايا، مما يمكّن سير عمل بدون لمس وتوسيع الدراسات لتشمل الملايين من الخلايا.
ستكون فرص الوصول المبكر متاحة وسيقدم كلا الشركتين تفاصيل في ASHG Annual Meeting، 14–18 أكتوبر 2025 (كشك BD 447؛ كشك Opentrons 635).
BD（NYSE: BDX）与 Opentrons 于 2025 年 10 月 8 日宣布了一项为期多年的合作，将 Opentrons 的机器人液体处理整合到 BD 的单细胞多组学仪器中。
该伙伴关系旨在将 BD Rhapsody 系统与 Opentrons Flex 平台整合，开发经过验证的协议，并构建一个与自动化兼容的模块，以实现下一代测序文库制备和细胞捕获的自动化，从而实现无手动干预的工作流并扩展到百万细胞研究。
将提供早期访问机会，双方将在 ASHG Annual Meeting，2025 年 10 月 14–18 日（BD 展位 447；Opentrons 展位 635）公布细节。
- Multi-year collaboration announced on Oct 8, 2025
- Integration of BD Rhapsody with Opentrons Flex platform
- Automation module for library preparation and cell capture
- Supports million-cell study workflows
- Early access program announced for labs at ASHG Oct 14–18, 2025
- None.
Insights
Multi-year collaboration pairs BD's single-cell platforms with Opentrons' robotics to scale and automate multiomics workflows.
Combining BD single-cell instruments, including the BD Rhapsody™ HT Xpress System, with the Opentrons Flex® platform creates a clear channel to move manual sample-prep steps into hands-free automation. The plan to develop verified protocols and an automation-compatible module for next-generation sequencing library preparation and cell capture directly addresses throughput and reproducibility barriers in large studies such as million-cell experiments.
Key dependencies include successful technical integration, protocol validation, and uptake through the announced early access program. Watch for demonstration outcomes at the
Integration targets automation of library prep and cell capture to improve scale, speed, and reproducibility for single-cell multiomics.
The technical scope focuses on integrating liquid-handling robotics with existing single-cell capture and library-prep steps. Automating those specific steps can reduce manual variation and increase throughput when paired with validated protocols. The announcement explicitly names the BD Rhapsody™ System and the Opentrons Flex® platform, and promises verified protocols and an automation-compatible module.
Risks include the need for tight hardware-software interfacing and successful verification across real-world sample types. Monitor availability of the automation module, published protocol verification, and early access feedback reported after the
"By revealing the multiple layers of biological information within cells, the field of single-cell multiomics is quickly transforming research in oncology, immunology and beyond – and automation can further accelerate adoption especially in translational and biopharma settings," said Ranga Partha, PhD, VP/GM of Global Marketing and Strategic Growth Areas, BD Biosciences. "By integrating robotics with our instruments – including the BD Rhapsody® HT Xpress System which enables million-cell studies – we are helping scientists access potentially life-changing insights with greater speed, scale and reproducibility."
The companies intend to integrate the BD Rhapsody™ System with the Opentrons Flex® platform, as well as develop verified protocols, allowing scientists to perform hands-free workflows with their single-cell multiomics experiments. A cornerstone of the collaboration is the development of an automation-compatible module for the BD Rhapsody™ System that will enable the steps of next-generation sequencing library preparation and cell capture to be automated.
"This collaboration brings together the long-standing expertise of BD in the field of single-cell multiomics with the flexible and open automation ecosystem of Opentrons," said James Atwood, PhD, CEO of Opentrons Labworks. "By combining our hardware platforms, we are making it easier and more cost-effective for labs everywhere, across basic and translational research, to perform cutting-edge single-cell sequencing at scale."
Early access opportunities for interested labs will be available soon. To learn more about the collaboration and the early access program, visit Opentrons (Booth 635) and BD (Booth 447) at the upcoming American Society of Human Genetics (ASHG) Annual Meeting in
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
About Opentrons
Opentrons Labworks, Inc., a disruptive life science company and the current market leader in entry-level lab automation, accelerates innovation in research and healthcare through its integrated lab platform. Opentrons has raised over
|
Contacts: |
|
|
|
|
|
Media: |
Investors: |
|
For BD: |
|
|
Fallon McLoughlin |
Adam Reiffe |
|
Director, Public Relations |
VP, Investor Relations |
|
201.258.0361 |
201.847.6927 |
|
|
|
|
For Opentrons: |
|
|
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-opentrons-collaborate-to-accelerate-single-cell-multiomics-discoveries-with-robotic-automation-302577700.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What did BD (BDX) and Opentrons announce on Oct 8, 2025?
How will the BD Rhapsody System change with the Opentrons integration?
What investor-relevant scale does BD cite for the Rhapsody system?
When and where can labs learn about BD and Opentrons early access?
What workflows will be automated by the collaboration?
How many Opentrons robotic systems are deployed today, per the announcement?
